Abstract
ABSTRACT
Overlap between psoriasis and atopic dermatitis (AD) poses diagnostic and therapeutic challenges; monoclonal antibodies targeting a single axis may improve one component while worsening the other [1]. Janus kinase (JAK) inhibitors act pleiotropically and may provide simultaneous control of psoriatic and eczematous inflammation [2]. We report four adult women with psoriatic–AD overlap phenotypes, refractory to conventional systemic agents and/or biologics. Three patients received upadacitinib (15–30 mg/day) and one received baricitinib (4 mg/day). Within 2–12 weeks, all patients experienced rapid pruritus relief and clinically meaningful improvement; two achieved near‐complete clearance of both psoriatic and eczematous components, one maintained rheumatologic stability despite prior biologic failures, and one showed partial response complicated by a superimposed cephalic infection requiring adjunctive therapy. In this small series, JAK inhibition provided practical, rapid control across dual inflammatory endotypes in psoriasis–AD overlap. Prospective studies are warranted to define patient selection, dose optimisation, durability, and safety.